EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment

Artem Berezovsky iD, Oluwademilade Nuga iD, Indrani Datta, Kimberly Bergman, Thais Sabedot iD, Katherine Gurdziel, Susan Irtenkauf, Laura Hasselbach, Yuling Meng, Claudius Mueller iD, Emanuel F Petricoin iD, Stephen Brown und 7 weitere

PLOS ONE · 07.02.2025 · 20 (2) · e0315171

DOI: 10.1371/journal.pone.0315171 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 07.02.2025. Verfasst von Artem Berezovsky und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Henry Ford Health, Detroit, Michigan, United States of America. Hauptthemen laut MEDLINE: Glioblastoma, Tumor Suppressor Protein p53, Signal Transduction, Interferons. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 106 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIEHS NIH HHS, U.S. Department of Defense.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma (GBM) tumors exhibit extensive genomic, epigenomic, and transcriptional diversity, with significant intratumoral heterogeneity, complicating standard treatment approaches involving radiation (RT) and the DNA-alkylating agent temozolomide (TMZ). In this study, we employed an integrative multi-omics approach, including targeted proteomics, transcriptomics, genomics, and DNA methylation profiling, to investigate the response of a representative panel of GBM patient-derived cancer stem cells (CSCs) to astrocytic differentiation and RT and TMZ treatments. Differentiated CSC progenies retained the expression of key stemness genes and survival pathways, while activating the BMP-Smad signaling pathway and upregulating extracellular matrix components. This was associated with increased resistance to TMZ, though not to RT, across all models. We identified TP53 status as a critical determinant of transcriptional response to both RT and TMZ, which was also modulated by the differentiation state and treatment modality in wildtype (wt) p53 GBM cells. Both mutant and wt p53 models exhibited significant activation of the DNA-damage associated interferon (IFN) response in CSCs and differentiated cells, implicating this pathway in the GBM response to therapy. We observed that activation of NF-κB was positively correlated with the levels of O-6-methylguanine-DNA methyltransferase (MGMT) protein, a direct DNA repair enzyme leading to TMZ resistance, regardless of MGMT promoter methylation status, further supporting the clinical potential for inhibition of NF-kB signaling in GBM treatment. Our integrative analysis of the impact of GBM cell developmental states, in the context of genomic and molecular diversity of patient-derived models, provides valuable insights for pre-clinical studies aimed at optimizing treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaTumor Suppressor Protein p53Signal TransductionInterferonsDacarbazineAntineoplastic Agents, AlkylatingBrain NeoplasmsHumansTemozolomideNeoplastic Stem CellsCell Line, TumorDNA MethylationCell DifferentiationGene Expression Regulation, NeoplasticDNA Modification MethylasesNF-kappa BDrug Resistance, NeoplasmDNA Repair EnzymesTumor Suppressor Proteins

Substanzen

TemozolomideTumor Suppressor Protein p53InterferonsDacarbazineAntineoplastic Agents, AlkylatingTP53 protein, humanDNA Modification MethylasesMGMT protein, humanNF-kappa BDNA Repair Enzymes

Autor:innen und Institutionen

  • Department of Neurosurgery, Henry Ford Health, Detroit, Michigan, United States of America.
  • Department of Oncology, Wayne State University, Detroit, Michigan, United States of America.
  • Department of Pharmacology, Wayne State University, Detroit, Michigan, United States of America.
  • Institute of Environmental Health Sciences, Wayne State University, Detroit, Michigan, United States of America.
  • Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, Virginia, United States of America.
  • Department of Radiation Oncology, Henry Ford Health, Detroit, Michigan, United States of America.

ORCID-Profile: Artem Berezovsky, Oluwademilade Nuga, Thais Sabedot, Claudius Mueller, Emanuel F Petricoin, Neeraja Purandare, Tom Mikkelsen, Laila Poisson, Houtan Noushmehr, Douglas Ruden, Ana C deCarvalho

Förderung

  • NCI NIH HHS
  • NIEHS NIH HHS
  • U.S. Department of Defense
  • National Cancer Institute
  • Demchik Family Fund for Glioma Patient-Derived Avatar Models

Zitieren

APA

Berezovsky, A., Nuga, O., Datta, I., Bergman, K., Sabedot, T., Gurdziel, K., Irtenkauf, S., Hasselbach, L., Meng, Y., Mueller, C., Petricoin, E. F., Brown, S., Purandare, N., Aras, S., Mikkelsen, T., Poisson, L., Noushmehr, H., Ruden, D., & deCarvalho, A. C. (2025). Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment. PLOS ONE, 20(2), e0315171. https://doi.org/10.1371/journal.pone.0315171

Vancouver

Berezovsky A, Nuga O, Datta I, Bergman K, Sabedot T, Gurdziel K, et al. Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment. PLOS ONE. 2025;20(2):e0315171. doi:10.1371/journal.pone.0315171

BibTeX
@article{Berezovsky2025,
  author = {Berezovsky, Artem and Nuga, Oluwademilade and Datta, Indrani and Bergman, Kimberly and Sabedot, Thais and Gurdziel, Katherine and Irtenkauf, Susan and Hasselbach, Laura and Meng, Yuling and Mueller, Claudius and Petricoin, Emanuel F and Brown, Stephen and Purandare, Neeraja and Aras, Sidhesh and Mikkelsen, Tom and Poisson, Laila and Noushmehr, Houtan and Ruden, Douglas and deCarvalho, Ana C},
  title = {Impact of developmental state, p53 status, and interferon signaling on glioblastoma cell response to radiation and temozolomide treatment},
  journal = {PLOS ONE},
  year = {2025},
  volume = {20},
  number = {2},
  pages = {e0315171},
  doi = {10.1371/journal.pone.0315171}
}
Kostenlos starten →